GlassScriptPhysician profile
Matthew Ross
NPI 1124601422
$7,302.78
in general payments reported to CMS, 2019-2025
27 companies · $2,094 in 2025
The $2,094 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $619 · 2022: $1,006 · 2023: $1,702 · 2024: $1,882 · 2025: $2,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,677.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,310.83 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,267.01 | 2021-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $840.52 | 2022-2025 | Livdelzi, Vemlidy |
| Janssen Biotech, INC. | $434.67 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $287.71 | 2022-2025 | Entyvio, Eohilia |
| Novo Nordisk INC | $234.74 | 2021-2025 | Wegovy |
| Celltrion USA INC. | $199.92 | 2024-2025 | Vegzelma |
| Ardelyx, INC. | $198.12 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $181.34 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $180.71 | 2023-2025 | Ocaliva |
| Biohaven Pharmaceuticals, INC. | $156.09 | 2021 | |
| Glaxosmithkline, LLC. | $124.99 | 2021 | |
| Braintree Laboratories, INC. | $122.58 | 2024-2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $115.89 | 2021-2024 | Dificid |
| Pfizer INC. | $113.56 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $96.12 | 2023 | |
| Vivus LLC | $74.00 | 2023-2025 | Pancreaze |
| Phathom Pharmaceuticals, INC. | $57.21 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $49.21 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $45.92 | 2021-2023 | Talicia, Aemcolo |
| Lilly USA, LLC | $40.80 | 2024 | Omvoh, Zepbound |
| Ironwood Pharmaceuticals, INC | $36.87 | 2024 | |
| Fresenius Kabi USA, LLC | $34.68 | 2025 | |
| Recordati_rare_diseases_inc. | $29.14 | 2025 | Panhematin |
| Celgene Corporation | $28.52 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $24.95 | 2025 | Rezdiffra |
| Qol Medical, LLC | $16.68 | 2024 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.